A targeted treatment designed to trigger the death of cancer cells has shown significant promise for patients with advanced bowel cancer when combined with chemotherapy, an early trial has revealed.
Researchers reported that the combination therapy led to tumour shrinkage in some patients and successfully halted the disease's progression in others.
